Wockhardt Ltd. has declared encouraging results for 1HFY03. While sales have grown by more than 20%, net profit forged ahead by 37%. The impressive performance in sales is on the back of strong growth in export formulations and key brands in the domestic market.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share
P/E (at current price)
Exports have registered a significant 44% growth in sales, now contributing more than 36% of the company's total sales. The growth in exports was mainly fuelled by increase in production capacity of Vitamin B12 and alliance with Ranbaxy. It may be recalled that the Wockhardt entered into a multi-product development, supply, sales and marketing alliance with Ranbaxy Labs. The alliance has introduced two products in the US markets (Enalapril and Ranitidine).
The increase in depreciation has been on account of new bio-technology manufacturing facility being set up by the company in Aurangabad to manufacture bio-technologically derived products. The company has incured Rs 169 m capex on this facility till date.
The biotech products of the company continue to log attractive growth rates. Wockhardt is expecting one product introduction every year from its biotech division. Besides these, the product lineup of the company seems to be strong with various combinational vaccines, typhoid vaccine and other drugs in lifestyle therapeutics (chronic segment). However, the company is expected to face stiff competition in all the areas it operates in. As far as the biotech products are concerned, though the company may have the first mover advantage in the domestic market, there are lot of other companies which have similar products in their pipeline. For example, both Cipla and Ranbaxy are planning to introduce Erthyopoitein; Shanta Biotech is targeting to produce human insulin. Considering this, it is unlikely that the company would be able to maintain its pricing power.
During the quarter, the company took over entire equity holding in Wockhardt Rhein Biopharm Ltd. (WRBL) WRBL was a joint venture company between Wockhardt Ltd. (WL) and Rhein Biotech GmbH, Germany, each holding 50% of the capital. WRBL is now a wholly owned subsidiary of Wockhardt.
At the current market price of Rs 472, the stock is currently trading at 16x annualised earnings for 1HFY03.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407